Fig. 4. EVAML incites inflammatory responses in HSPCs in vivo.
A B6 CD45.1 mice were serially injected with AF9-EVAML (2E9 particles/day) for 3 days (n = 3). Mice received either PBS or PB-EV (2E9 particles/day) served as negative controls. HSPCs from injected mice were harvested 24 h the last injection and subjected to RNA-Seq analysis. Volcano plots illustrating differential HSPCs gene expression between: (B) PB-EV and (C) AF9-EVAML. D GSEA analysis of differential expressed genes in HSPCs from AF9-EVAML showed enriched inflammatory related pathways compared to vehicle control (PBS-injected). E Heatmap of top 20 inflammatory targets significantly upregulated in HSPCs from AF9-EVAML- (top), PB-EV- (mid), and LPS- injected (lower panel) mice compared to vehicle control (PBS-injected).